Literature DB >> 25054358

Current advances in understanding and managing secondary brain metastasis.

Radhika Dasararaju1, Amitkumar Mehta.   

Abstract

Metastatic brain tumors are the number one cause of intracranial neoplasms in adults and are associated with higher morbidity and mortality. The frequency of metastatic brain tumors is increasing because of improved survival in cancer patients. The molecular mechanism of brain metastasis is complex and not completely known. Vasogenic edema produced by tumor-derived VEGF is responsible for clinical symptoms. Dexamethasone remains the mainstay of medical management with not completely known mechanisms of action. Surgery and radiation are the main treatment modalities for metastatic brain tumors. Systemic chemotherapy has a very limited role in treatment of these tumors. Leptomeningeal metastasis is associated with extremely poor outcome.

Entities:  

Mesh:

Year:  2013        PMID: 25054358      PMCID: PMC6169476          DOI: 10.2217/cns.12.33

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


  76 in total

1.  Radiosurgery followed by planned observation in patients with one to three brain metastases.

Authors:  Johannes Lutterbach; Donatus Cyron; Karl Henne; Christoph B Ostertag
Journal:  Neurosurgery       Date:  2003-05       Impact factor: 4.654

2.  Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells.

Authors:  M R Machein; J Kullmer; V Rönicke; U Machein; M Krieg; A Damert; G Breier; W Risau; K H Plate
Journal:  Neuropathol Appl Neurobiol       Date:  1999-04       Impact factor: 8.090

3.  Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis.

Authors:  Michal Mego; Zuzana Sycova-Mila; Jana Obertova; Jan Rajec; Stefania Liskova; Patrik Palacka; Stefan Porsok; Jozef Mardiak
Journal:  Breast       Date:  2011-06-23       Impact factor: 4.380

Review 4.  Emerging molecular mechanisms of brain tumour oedema.

Authors:  M C Papadopoulos; S Saadoun; D C Davies; B A Bell
Journal:  Br J Neurosurg       Date:  2001-04       Impact factor: 1.596

Review 5.  Thrombosis in cancer patients.

Authors:  H F Hillen
Journal:  Ann Oncol       Date:  2000       Impact factor: 32.976

6.  A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104.

Authors:  K J Murray; C Scott; H M Greenberg; B Emami; M Seider; N L Vora; C Olson; A Whitton; B Movsas; W Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-10-01       Impact factor: 7.038

Review 7.  Management of venous thromboembolism in patients with primary and metastatic brain tumors.

Authors:  David E Gerber; Stuart A Grossman; Michael B Streiff
Journal:  J Clin Oncol       Date:  2006-03-10       Impact factor: 44.544

8.  Distribution of brain metastases.

Authors:  J Y Delattre; G Krol; H T Thaler; J B Posner
Journal:  Arch Neurol       Date:  1988-07

9.  Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis.

Authors:  J Strugar; D Rothbart; W Harrington; G R Criscuolo
Journal:  J Neurosurg       Date:  1994-10       Impact factor: 5.115

10.  Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline.

Authors:  May N Tsao; Dirk Rades; Andrew Wirth; Simon S Lo; Brita L Danielson; Laurie E Gaspar; Paul W Sperduto; Michael A Vogelbaum; Jeffrey D Radawski; Jian Z Wang; Michael T Gillin; Najeeb Mohideen; Carol A Hahn; Eric L Chang
Journal:  Pract Radiat Oncol       Date:  2012-01-30
View more
  3 in total

1.  The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.

Authors:  David P Kodack; Vasileios Askoxylakis; Gino B Ferraro; Qing Sheng; Mark Badeaux; Shom Goel; Xiaolong Qi; Ram Shankaraiah; Z Alexander Cao; Rakesh R Ramjiawan; Divya Bezwada; Bhushankumar Patel; Yongchul Song; Carlotta Costa; Kamila Naxerova; Christina S F Wong; Jonas Kloepper; Rita Das; Angela Tam; Jantima Tanboon; Dan G Duda; C Ryan Miller; Marni B Siegel; Carey K Anders; Melinda Sanders; Monica V Estrada; Robert Schlegel; Carlos L Arteaga; Elena Brachtel; Alan Huang; Dai Fukumura; Jeffrey A Engelman; Rakesh K Jain
Journal:  Sci Transl Med       Date:  2017-05-24       Impact factor: 17.956

2.  Expression of Vascular Endothelial Growth Factor A and Its Type 1 Receptor in Supratentorial Neoplasm.

Authors:  Hamid Rezaee; Shadi Abbasnia; Anita Alenabi; Rosita Vakili; Nasrin Moheghi; Jalil Tavakol Afshari; Seyed Abdolrahim Rezaee
Journal:  Rep Biochem Mol Biol       Date:  2021-10

3.  The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review.

Authors:  Kyra X Swildens; Peter A E Sillevis Smitt; Martin J van den Bent; Pim J French; Marjolein Geurts
Journal:  Neurooncol Adv       Date:  2022-06-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.